Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6691 to 6705 of 7691 results

  1. Hernia

    Discontinued [GID-CGWAVE0771]

    NICE guideline
    Discontinued

  2. Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]

    Discontinued [GID-TAG300]

    Technology appraisal guidance
    Discontinued

  3. Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]

    Discontinued [GID-TAG403]

    Technology appraisal guidance
    Discontinued

  4. Nivolumab with ipilimumab for untreated non-small-cell lung cancer that has a high tumour mutational burden [ID1187]

    Discontinued [GID-TA10234]

    Technology appraisal guidance
    Discontinued

  5. Nintedanib for treating interstitial lung disease caused by systemic sclerosis [ID1420]

    Discontinued [GID-TA10427]

    Technology appraisal guidance
    Discontinued

  6. Lenalidomide for untreated follicular lymphoma ID1245

    Discontinued [GID-TA10308]

    Technology appraisal guidance
    Discontinued

  7. Venous thromboembolism - apixaban (acute medical illness) [ID310]

    Discontinued [GID-TAG419]

    Technology appraisal guidance
    Discontinued

  8. Nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer [ID1135]

    Discontinued [GID-TA10233]

    Technology appraisal guidance
    Discontinued

  9. Osteoarthritis - naproxcinod [ID417]

    Discontinued [GID-TAG426]

    Technology appraisal guidance
    Discontinued

  10. Atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [ID1674]

    Discontinued [GID-TA10543]

    Technology appraisal guidance
    Discontinued

  11. Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer [ID1509]

    Discontinued [GID-TA10413]

    Technology appraisal guidance
    Discontinued

  12. Durvalumab with tremelimumab for untreated non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1143]

    Discontinued [GID-TA10186]

    Technology appraisal guidance
    Discontinued

  13. Masitinib for the treatment of locally advanced or metastatic pancreatic cancer [ID566]

    Discontinued [GID-TAG330]

    Technology appraisal guidance
    Discontinued

  14. Ligelizumab for previously treated chronic spontaneous urticaria in people 12 years and over [ID3999]

    Discontinued [GID-TA10891]

    Technology appraisal guidance
    Discontinued

  15. Rovalpituzumab tesirine for treating small-cell lung cancer after 2 therapies [ID1288]

    Discontinued [GID-TA10212]

    Technology appraisal guidance
    Discontinued